| 초록 |
Among recent developments in cancer immunotherapy, immune checkpoint blockade (ICB), which targets regulatory pathways in T cells to augment anti-tumor responses, has shown remarkable clinical benefits for various types of cancers. However, despite the great promise of immune checkpoint blockade (ICB) therapy for cancer treatment, the currently available options for ICB treatment pose major clinical challenges, including the risk of severe systemic autoimmune responses. Here, we developed a novel localized delivery platform, immuno-glue (imuGlue), which is inspired by the intrinsic underwater adhesion properties of marine mussels and can allow the optimal retention of anti-PD-L1 drugs at tumor sites and the on-demand release of drugs in response to the tumor microenvironment. This platform can be applied with a spray or injection system for postsurgical treatment and via intratumoral injection for preoperative treatment and/or unresectable locally advanced cancers, demonstrating its versatility as a new treatment option for cancer immunotherapy. |
